Long-term impact of COVID-19 hospitalisation among individuals with pre-existing airway diseases in the UK: a multicentre, longitudinal cohort study - PHOSP-COVID.

Autor:	Elneima O; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Hurst JR; UCL Respiratory, Department of Medicine, University College London, London, UK.; Royal Free London NHS Foundation Trust, London, UK., Echevarria C; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.; Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK., Quint JK; School of Public Health, Imperial College London, London, UK., Walker S; Asthma+Lung UK, London, UK., Siddiqui S; National Heart and Lung Institute, Imperial College London, London, UK., Novotny P; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Pfeffer PE; Department of Respiratory Medicine, Barts Health NHS Trust, London, UK.; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Brown JS; UCL Respiratory, Department of Medicine, University College London, London, UK., Shankar-Hari M; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK., McAuley HJC; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Leavy OC; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK.; Department of Population Health Sciences, University of Leicester, Leicester, UK., Shikotra A; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Singapuri A; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Sereno M; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Richardson M; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Saunders RM; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Harris VC; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Houchen-Wolloff L; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK.; Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK., Greening NJ; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Harrison EM; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK., Docherty AB; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK., Lone NI; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK., Chalmers JD; University of Dundee, Ninewells Hospital and Medical School, Dundee, UK., Ho LP; MRC Translational Discovery Immunology Unit, University of Oxford, Oxford, UK.; NIHR Oxford BRC, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Horsley A; Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.; Manchester University NHS Foundation Trust, Manchester, UK., Marks M; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.; Hospital for Tropical Diseases, University College London Hospital, London, UK., Poinasamy K; Asthma+Lung UK, London, UK., Raman B; NIHR Oxford BRC, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK., Evans RA; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK., Wain LV; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK.; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK., Sheikh A; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK., Brightling CE; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK.; Joint senior authors., De Soyza A; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.; Joint senior authors., Heaney LG; Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, UK.; Belfast Health and Social Care Trust, Belfast, UK.; Joint senior authors.
Jazyk:	angličtina
Zdroj:	ERJ open research [ERJ Open Res] 2024 Jul 15; Vol. 10 (4). Date of Electronic Publication: 2024 Jul 15 (Print Publication: 2024).
DOI:	10.1183/23120541.00982-2023
Abstrakt:	Background: The long-term outcomes of COVID-19 hospitalisation in individuals with pre-existing airway diseases are unknown. Methods: Adult participants hospitalised for confirmed or clinically suspected COVID-19 and discharged between 5 March 2020 and 31 March 2021 were recruited to the Post-hospitalisation COVID-19 (PHOSP-COVID) study. Participants attended research visits at 5 months and 1 year post discharge. Clinical characteristics, perceived recovery, burden of symptoms and health-related quality of life (HRQoL) of individuals with pre-existing airway disease ( i.e. , asthma, COPD or bronchiectasis) were compared to the non-airways group. Results: A total of 615 out of 2697 (22.8%) participants had a history of pre-existing airway diseases (72.0% diagnosed with asthma, 22.9% COPD and 5.1% bronchiectasis). At 1 year, the airways group participants were less likely to feel fully recovered (20.4% versus 33.2%, p<0.001), had higher burden of anxiety (29.1% versus 22.0%, p=0.002), depression (31.2% versus 24.7%, p=0.006), higher percentage of impaired mobility using short physical performance battery ≤10 (57.4% versus 45.2%, p<0.001) and 27% had a new disability (assessed by the Washington Group Short Set on Functioning) versus 16.6%, p=0.014. HRQoL assessed using EQ-5D-5L Utility Index was lower in the airways group (mean±SD 0.64±0.27 versus 0.73±0.25, p<0.001). Burden of breathlessness, fatigue and cough measured using a study-specific tool was higher in the airways group. Conclusion: Individuals with pre-existing airway diseases hospitalised due to COVID-19 were less likely to feel fully recovered, had lower physiological performance measurements, more burden of symptoms and reduced HRQoL up to 1 year post-hospital discharge. Competing Interests: Conflict of interest: J.R. Hurst has received support to attend meetings, research grants, and personal payment and payment to his employer from pharmaceutical companies that make medicines to treat airways diseases. J.K. Quint reports grants from Industrial Strategy Challenge Fund, the Medical Research Council, Health Data Research, GlaxoSmithKline (GSK), Boehringer Ingelheim (BI), Asthma+Lung UK and AstraZeneca (AZ), and consulting fees from GSK, Evidera, Chiesi, AZ and Insmed outside the submitted work. P.E. Pfeffer reports grants from NIHR and GSK, Honoraria payments for lectures from AZ, GSK, Sanofi and Chiesi and travel fees from AZ, GSK, Sanofi outside the submitted work. N.J. Greening reports grants from GSK and BioAge, and personal fees and travel grants from Genentech, Roche, Chiesi, AZ, GSK, Pulmonx and Chiesi outside the submitted work. J.D. Chalmers is an associate editor of this journal. A. Horsley reports grants from UKRI, NIHR and NIHR Manchester BRC during the conduct of this study and unenumerated role as the chair of NIHR Translational Research Collaboration. A. Sheikh has served on AZ's thrombotic thrombocytopenic taskforce, and on a number of UK and Scottish Government COVID-19 advisory bodies; all these roles were unremunerated. B. Raman reports grant from BHF Oxford CRE and speaker fees from Axcella Therapeutics. R.A. Evans reports grants from UKRI/MRC, DHSC/NIHR, Wolfson Foundation and Genentec/Roche during the conduct of this study, travel and speaker fees from AZ/Evidera, Boehringer Ingelheim (BI), Moderna and Chiesi, and unremunerated leadership roles in ERS/ATS outside the submitted work. C.E. Brightling declares that their institute was awarded a grant from UKRI/NIHR to complete this work; the author reports grants from GSK, AZ, Sanofi, Regeneron, BI, Chiesi, Novartis, Roche, Genentech, Mologic and 4DPharma; and consultancy fees paid to their institution from GSK, AZ, Sanofi, BI, Chiesi, Novartis, Roche, Genentech, Mologic, 4DPharma and Areteia. A. De Soyza declares receiving personal consulting fees and travel grants from AZ, Bayer, GSK, Chiesi, Novartis, Pfizer, Insmed, Gilead and 30T outside the submitted work. All other authors declare no competing interests. (Copyright ©The authors 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu